Observational studyThe journal of headache and pain2026

Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.

Emmanouil V Dermitzakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.